

Nigeria

Support for Vaccine: DTP-HepB-Hib

This Decision Letter sets out the Programme Terms of a Programme.

1.	Country:	Nigeria																					
2.	Vaccine grant number:	NGA-PENTA-R, NGA-PENTA-R-VIG, NGA-PENTA-R-VAC																					
3.	Date of Decision Letter:	08/11/2019																					
4.	Date of the Partnership Framework Agreement:	09/03/2014																					
5.	Programme title:	New Vaccine Support (NVS), DTP-HepB-Hib, Routine																					
6.	Vaccine type:	DTP-HepB-Hib																					
7.	Requested product presentation and formulation of vaccine:	Penta, 10 dose(s) per vial, LIQUID																					
8.	Programme Duration:¹	2012-2020																					
9.	Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement, if applicable)																					
		2012-2019	2020	2021	2022	2023	2024	Total ²															
	Programme Budget (US\$)	146,885,696	3,395,159	-	-	-	-	150,280,855															
10.	Vaccine introduction grant	<table border="1" style="width: 100%; border-collapse: collapse; margin-bottom: 10px;"> <thead> <tr> <th colspan="3" style="text-align: center;">Approval</th> </tr> <tr> <th style="width: 15%;">Year</th> <th style="width: 45%;">Grant Number</th> <th style="width: 40%;">Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">2012</td> <td style="text-align: center;">NGA-PENTA-R-VIG</td> <td style="text-align: right;">4,311,474</td> </tr> </tbody> </table> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th colspan="2" style="text-align: center;">Disbursement</th> </tr> <tr> <th style="width: 45%;">Disbursement date</th> <th style="width: 55%;">Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">27 September, 2013</td> <td style="text-align: right;">4,311,474</td> </tr> </tbody> </table>							Approval			Year	Grant Number	Amount (US\$)	2012	NGA-PENTA-R-VIG	4,311,474	Disbursement		Disbursement date	Amount (US\$)	27 September, 2013	4,311,474
Approval																							
Year	Grant Number	Amount (US\$)																					
2012	NGA-PENTA-R-VIG	4,311,474																					
Disbursement																							
Disbursement date	Amount (US\$)																						
27 September, 2013	4,311,474																						
11.	Product switch grant	Not applicable																					
12.	Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement, if applicable)																					
	Type of supplies to be purchased with Gavi funds	2012-2019	2020					2021															
	Number of vaccine doses		4,471,402					-															

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

Number of AD Syringes		3,698,315																																											
Number of Reconstitution Syringes																																													
Number of Safety Boxes		40,684																																											
Annual Amounts (US\$)	146,885,696	3,395,159	-																																										
13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.																																												
14. Self-procurement:	Not applicable																																												
15. Co-financing obligations:	<p>According to the co-financing policy, the Country falls within the group: Accelerated transition phase</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2020</th> <th>2021</th> <th>2022</th> <th>2023</th> <th>2024</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>19,906,500</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Number of AD syringes</td> <td>16,463,860</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Number of re-constitution syringes</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Number of safety boxes</td> <td>181,116</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>13,934,413</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>15,114,301</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> </tbody> </table>			Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024	Number of vaccine doses	19,906,500	-	-	-	-	Number of AD syringes	16,463,860	-	-	-	-	Number of re-constitution syringes	-	-	-	-	-	Number of safety boxes	181,116	-	-	-	-	Value of vaccine doses (US\$)	13,934,413	-	-	-	-	Total co-financing payments (US\$) (including freight)	15,114,301	-	-	-	-
Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024																																								
Number of vaccine doses	19,906,500	-	-	-	-																																								
Number of AD syringes	16,463,860	-	-	-	-																																								
Number of re-constitution syringes	-	-	-	-	-																																								
Number of safety boxes	181,116	-	-	-	-																																								
Value of vaccine doses (US\$)	13,934,413	-	-	-	-																																								
Total co-financing payments (US\$) (including freight)	15,114,301	-	-	-	-																																								
16. Operational support for campaigns:	Not applicable																																												
17. Additional Reporting Requirements:	<table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. </td> <td> 31 March 2020 15 May 2020 </td> </tr> </tbody> </table>				Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2020 15 May 2020																																						
	Due dates																																												
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2020 15 May 2020																																												



In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
18. Financial clarifications: Country shall provide the following clarifications to Gavi*: Not applicable * Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.	
19. Other conditions: Not applicable	

Signed by,

On behalf of Gavi

A handwritten signature in black ink, appearing to read "Thabani Maphosa".

Thabani Maphosa
Managing Director, Country Programmes
Friday, November 8, 2019